AMOTL2: A Potential Drug Target and Biomarker for Angiomotin-Like Protein 2

Target Name: AMOTL2

NCBI ID: G51421

AMOTL2

AMOTL2: A Potential Drug Target and Biomarker for Angiomotin-Like Protein 2

Angiomotin-like protein 2 (AMOTL2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. AMOTL2 is a 21-kDa protein that is expressed in various tissues and organs, including the brain, heart, liver, and kidneys. It is characterized by a unique N-terminus that contains a conserved region similar to that of the protein tyrosine kinase (PTK), which is a key regulator of cell growth and survival.

The Structure and Function of AMOTL2

The structure of AMOTL2 is unique, as it contains a N-terminal region that is highly conserved and includes a putative ATP-binding site, a catalytic domain, and a carboxylic acid residue. The catalytic domain is responsible for the protein's function and is similar to that of other tyrosine kinases, including PTK. The carboxylic acid residue is important for the protein's stability and functions as a ligand for other proteins, including PTK.

AMOTL2 has been shown to play a role in various physiological processes, including cell growth, differentiation, and survival. It has been shown to promote the growth of cancer cells and to contribute to neurodegenerative diseases. In addition, AMOTL2 has been shown to be involved in the regulation of inflammation and immune responses.

The Potential Role of AMOTL2 as a Drug Target

The potential role of AMOTL2 as a drug target is based on its involvement in various diseases and its unique structure. One of the main targets of AMOTL2 is the regulation of cell growth and survival. Cancer cells have been shown to have increased levels of AMOTL2, which may contribute to their ability to grow and evade the effects of chemotherapy.

AMOTL2 has also been shown to play a role in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial plaques. AMOTL2 has been shown to be involved in the regulation of these processes, which may make it a potential target for therapies aimed at treating these conditions.

In addition, AMOTL2 has been shown to be involved in the regulation of inflammation and immune responses. This may contribute to its potential as a drug target for diseases characterized by inflammation, such as rheumatoid arthritis and inflammatory bowel disease.

The Potential as a Biomarker

AMOTL2 has also been shown to be a potential biomarker for various diseases. This is because it is expressed in various tissues and can be detected using techniques such as Western blotting, immunofluorescence, and mass spectrometry. The detection of AMOTL2 in these tissues may be used as a diagnostic or monitoring tool for diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases.

Conclusion

AMOTL2 is a unique and potentially important protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function, as well as its involvement in various physiological processes, make it an attractive target for further research and development. Further studies are needed to fully understand the role of AMOTL2 in diseases and to develop effective therapies aimed at targeting it.

Protein Name: Angiomotin Like 2

Functions: Regulates the translocation of phosphorylated SRC to peripheral cell-matrix adhesion sites. Required for proper architecture of actin filaments. Inhibits the Wnt/beta-catenin signaling pathway, probably by recruiting CTNNB1 to recycling endosomes and hence preventing its translocation to the nucleus. Participates in angiogenesis. May play a role in the polarity, proliferation and migration of endothelial cells. Selectively promotes FGF-induced MAPK activation through SRC

The "AMOTL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMOTL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets